{"name":"LAVA Therapeutics","slug":"lava","ticker":"LVTX","exchange":"NASDAQ","domain":"lavatherapeutics.com","description":"LAVA Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, targeted T-cell therapies for the treatment of cancer. The company's lead product candidate, LAVA-1201, is a bispecific T-cell engager targeting the CD3 receptor and the CD47 receptor. LAVA Therapeutics is positioned to address the growing immuno-oncology market with its innovative approach to cancer treatment.","hq":"Utrecht, Netherlands","founded":0,"employees":"","ceo":"Michael Kosloski","sector":"Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":11982000,"revenueGrowth":77,"grossMargin":0,"rdSpend":28450000,"netIncome":-25114000,"cash":80831000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"LAVA Therapeutics Announces FDA Clearance of IND for LAVA-1201","summary":"LAVA Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for LAVA-1201, enabling the company to initiate a Phase 1 clinical trial.","drugName":"LAVA-1201","sentiment":"positive"},{"date":"2022-11-14","type":"deal","headline":"LAVA Therapeutics Enters into Collaboration with Merck KGaA","summary":"LAVA Therapeutics announced a collaboration with Merck KGaA to develop and commercialize LAVA-1201 in the United States and Canada.","drugName":"LAVA-1201","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAtWU5yR21vSHNXTWRiakR0b0xTMUlFLWVDbXktcGhFUl9DSUhFLTltTVdtQ3BIeEZ5bnVzNmc4X2dsLUw0WXF3Y2hXT3NuVl9hTEVhM09ELWdkV2JIWm9RMDZWbFA4ajNCOVZPMXN3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in LAVA Therapeutics N.V. (LVTX) - Stock Titan","headline":"If You Invested $1,000 in LAVA Therapeutics N.V. (LVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPbnJGbzZFdWFSUnhzRzFMT2FqbmZoaEoyaHVTQy1yVWU0ekRZWXFVQ3FPcGdYNVkwSGYzWEsyOEFyWTNnNmlUajJyYndrbFVva2dCaXJDZmszLUZ5T21yVXJZcmF3anhEZW52YWVzMEdVRmR1V2VMVGZCVUhLMEUxOXlRZ29fMDR1VzJPS1paRmJXN1k?oc=5","date":"2025-11-21","type":"deal","source":"Yahoo Finance","summary":"XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - Yahoo Finance","headline":"XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.","sentiment":"neutral"},{"date":"2025-11-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUTIwTm1hR2x0MVJXY19HRzNnRjRNdU1GVFc3Q3A5bnhpaDlxRC0wS0ctTnZNdV8wVmZhZ0hiTlM5Vno2eFY3bWZoVWFmSFg1c1J6bTJpSG5FVF9jbXgwZW44S2hsLUpBbDNwZ0Y4czctYU0tejF6SG0wZVoyWjN4LUZ3OXNVZl9USTM4YWp6ZGVQZzVOYmhybVFGdHNEd2k2MXB4MDlxTkRTU3NxMGh4VjF1VHNKTGFkVUM5OUNvR25naEk?oc=5","date":"2025-11-13","type":"pipeline","source":"Stock Titan","summary":"LVTX tender results: 22.88M shares tendered; delisting expected - Stock Titan","headline":"LVTX tender results: 22.88M shares tendered; delisting expected","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5tc2QtNkF4MmhyYmxsanZhR3k4Z2tkQ0s1cXVJT1B0d280LVJCMUllQWE1LXF3enlLV05VN1lxc0FYTHNla2JVUGQ5c294WFBGQ0Vn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KAPA Stock Price, News & Analysis - Stock Titan","headline":"KAPA Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5XZnp6UkY3ZGFsUkdrWjBDU1N2X1A1eDVOSDdFNG1qWWpGOWtlUmtQOVpqS3lZVnR5eENmb1c5ZmtKaVk4TWp4enRrY1ZNdEN5SWFYeXc5RHlBTVJvdEJWLVRIUzFtMFdvMWFDVXNDNFVtQWo5YXRsNG9RRQ?oc=5","date":"2024-08-08","type":"deal","source":"24/7 Wall St.","summary":"4 Stocks Under $5 To Buy Now - 24/7 Wall St.","headline":"4 Stocks Under $5 To Buy Now - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBEYWktTmtLeUdpLXI2b05CWWNLLUpPcUFFWFdBT0RucnhRTm84eEpvYTc0VEJyQ3FaYmhQbks1dFNNQUFNV1Q2ZGlqaTdSN1Q1Mk5PcFM4LUlXdS1iQW9N?oc=5","date":"2021-08-15","type":"pipeline","source":"ChartMill","summary":"LVTX Stock Price, Quote & Chart | LAVA Therapeutics NV (NASDAQ:LVTX) - ChartMill","headline":"LVTX Stock Price, Quote & Chart | LAVA Therapeutics NV (NASDAQ:LVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBoVDVsNy16TG5xRnRoNDdGbTVtZTJnSTRoUURrWG9waXdqZkN6MC1WQzUwa01FSGpnQmtsTnJyM3FnZGNIM1dvSWFoMlI2aEFWejlCX3IwVHVWV0JFekt1dWlJZ1dpdw?oc=5","date":"2021-04-12","type":"earnings","source":"MarketBeat","summary":"LAVA Therapeutics (LVTX) Earnings Date and Reports 2026 $LVTX - MarketBeat","headline":"LAVA Therapeutics (LVTX) Earnings Date and Reports 2026 $LVTX","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9oYmxCdkZLbmNTb2Q3TzZOd0ZNSkg2R1FwMHU1NGZFSE9XVVpkN3laVk5WQjhzR295ck5RbXgzUkpERV9LTUtJb3RDTFl4am1yLVJ3N3JlUEpMdw?oc=5","date":"2021-03-26","type":"pipeline","source":"MarketBeat","summary":"LAVA Therapeutics (LVTX) Stock Price, News & Analysis $LVTX - MarketBeat","headline":"LAVA Therapeutics (LVTX) Stock Price, News & Analysis $LVTX","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":11982000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":11982000,"period":"2024-12-31"},{"value":6769000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":28450000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-25114000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":80831000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}